Pfizer Inc. (NYSE:PFE) Shares Bought by BCS Wealth Management

BCS Wealth Management raised its holdings in Pfizer Inc. (NYSE:PFE) by 2.4% in the first quarter, Holdings reports. The fund owned 24,832 shares of the biopharmaceutical company’s stock after buying an additional 572 shares during the quarter. BCS Wealth Management’s holdings in Pfizer were worth $900,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in PFE. Kinloch Capital LLC acquired a new position in shares of Pfizer during the 4th quarter worth $25,000. Alpha DNA Investment Management LLC purchased a new stake in Pfizer during the 4th quarter worth about $26,000. Penbrook Management LLC purchased a new stake in Pfizer during the 4th quarter worth about $27,000. Orion Capital Management LLC purchased a new stake in Pfizer in the 4th quarter valued at about $29,000. Finally, Merrion Investment Management Co LLC purchased a new stake in Pfizer in the 4th quarter valued at about $30,000. 67.36% of the stock is owned by institutional investors and hedge funds.

Shares of Pfizer stock opened at $39.95 on Tuesday. The stock has a 50-day moving average price of $37.02 and a 200 day moving average price of $36.78. The company has a market cap of $222.83 billion, a P/E ratio of 25.70, a P/E/G ratio of 2.79 and a beta of 0.70. The company has a current ratio of 1.40, a quick ratio of 1.13 and a debt-to-equity ratio of 0.76. Pfizer Inc. has a 1 year low of $31.61 and a 1 year high of $43.08.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, February 2nd. The biopharmaceutical company reported $0.42 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.46 by ($0.04). Pfizer had a return on equity of 24.88% and a net margin of 17.85%. The business had revenue of $11.68 billion during the quarter, compared to analysts’ expectations of $11.32 billion. During the same period in the prior year, the company posted $0.55 earnings per share. The firm’s revenue was up 11.8% on a year-over-year basis. On average, equities analysts forecast that Pfizer Inc. will post 2.89 earnings per share for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Friday, June 4th. Investors of record on Friday, May 7th will be given a dividend of $0.39 per share. The ex-dividend date is Thursday, May 6th. This represents a $1.56 annualized dividend and a dividend yield of 3.90%. Pfizer’s dividend payout ratio (DPR) is presently 52.88%.

Several analysts have commented on the company. JPMorgan Chase & Co. set a $36.00 price target on Pfizer and gave the company a “neutral” rating in a report on Wednesday, February 3rd. TheStreet lowered Pfizer from a “b” rating to a “c+” rating in a research report on Friday, March 5th. SVB Leerink reduced their price target on Pfizer from $40.00 to $39.00 and set a “market perform” rating on the stock in a research report on Thursday, April 1st. DZ Bank reaffirmed a “buy” rating and issued a $41.00 target price on shares of Pfizer in a research report on Wednesday, February 3rd. Finally, Berenberg Bank reiterated a “neutral” rating and issued a $38.00 price target on shares of Pfizer in a report on Tuesday, March 23rd. Eleven analysts have rated the stock with a hold rating and three have given a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average price target of $38.47.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and pain under the Eliquis, Chantix/Champix, and Premarin family brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zithromax, Vfend, and Panzyga brands.

Further Reading: Street Name

Want to see what other hedge funds are holding PFE? Visit to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with's FREE daily email newsletter.